These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 32590815

  • 1. Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison.
    Ismail G, Obrişcă B, Jurubiţă R, Andronesi A, Sorohan B, Vornicu A, Sinescu I, Hârza M.
    Medicine (Baltimore); 2020 Jun 26; 99(26):e21000. PubMed ID: 32590815
    [Abstract] [Full Text] [Related]

  • 2. An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression.
    Obrișcă B, Vornicu A, Mocanu V, Dimofte G, Andronesi A, Bobeică R, Jurubiță R, Sorohan B, Caceaune N, Ismail G.
    Sci Rep; 2023 Nov 17; 13(1):20119. PubMed ID: 37978255
    [Abstract] [Full Text] [Related]

  • 3. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria.
    Smerud HK, Bárány P, Lindström K, Fernström A, Sandell A, Påhlsson P, Fellström B.
    Nephrol Dial Transplant; 2011 Oct 17; 26(10):3237-42. PubMed ID: 21378156
    [Abstract] [Full Text] [Related]

  • 4. [Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN)].
    Nagy J, Sági B, Máté J, Vas T, Kovács T.
    Orv Hetil; 2017 Dec 17; 158(49):1946-1952. PubMed ID: 29199436
    [Abstract] [Full Text] [Related]

  • 5. Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score: A single‑center cohort study.
    Tang Y, He H, Sun W, Hu P, Chen X, Xu X.
    Mol Med Rep; 2018 Oct 17; 18(4):4103-4112. PubMed ID: 30132546
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of corticosteroid therapy for IgA nephropathy patients stratified by kidney function and proteinuria.
    Nagasawa Y, Yamamoto R, Shinzawa M, Shoji T, Hasuike Y, Nagatoya K, Yamauchi A, Hayashi T, Kuragano T, Moriyama T, Isaka Y.
    Clin Exp Nephrol; 2020 Oct 17; 24(10):927-934. PubMed ID: 32642919
    [Abstract] [Full Text] [Related]

  • 7. Combination therapy of low-dose cyclosporine and steroid in adults with IgA nephropathy
.
    Ihm HS, Lee JY, Hwang HS, Kim YG, Moon JY, Lee SH, Jeong KH, Lee TW, Ihm CG.
    Clin Nephrol; 2019 Sep 17; 92(3):131-140. PubMed ID: 31232271
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study.
    Yang YZ, Chen P, Liu LJ, Cai QQ, Shi SF, Chen YQ, Lv JC, Zhang H.
    BMC Nephrol; 2019 Aug 05; 20(1):297. PubMed ID: 31382914
    [Abstract] [Full Text] [Related]

  • 9. Insights on Nefecon®, a Targeted-Release Formulation of Budesonide and Its Selective Immunomodulatory Effects in Patients with IgA Nephropathy.
    Barratt J, Kristensen J, Pedersen C, Jerling M.
    Drug Des Devel Ther; 2024 Aug 05; 18():3415-3428. PubMed ID: 39100224
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
    Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J, NefIgArd trial investigators.
    Lancet; 2023 Sep 09; 402(10405):859-870. PubMed ID: 37591292
    [Abstract] [Full Text] [Related]

  • 11. Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study.
    Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts IS, Cattran D, Coppo R, VALIGA study of the ERA-EDTA Immunonephrology Working Group.
    J Am Soc Nephrol; 2015 Sep 09; 26(9):2248-58. PubMed ID: 25677392
    [Abstract] [Full Text] [Related]

  • 12. Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review.
    Liao J, Zhou Y, Xu X, Huang K, Chen P, Wu Y, Jin B, Hu Q, Chen G, Zhao S.
    Front Immunol; 2022 Sep 09; 13():926517. PubMed ID: 36685528
    [Abstract] [Full Text] [Related]

  • 13. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
    Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L, NEFIGAN Trial Investigators.
    Lancet; 2017 May 27; 389(10084):2117-2127. PubMed ID: 28363480
    [Abstract] [Full Text] [Related]

  • 14. Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy.
    Sarcina C, Tinelli C, Ferrario F, Pani A, De Silvestri A, Scaini P, Del Vecchio L, Alberghini E, Buzzi L, Baragetti I, Pozzi C.
    Clin J Am Soc Nephrol; 2016 Jun 06; 11(6):973-981. PubMed ID: 27129712
    [Abstract] [Full Text] [Related]

  • 15. An update on corticosteroid treatment for IgA nephropathy.
    Ghaddar M, Barratt J, Barbour SJ.
    Curr Opin Nephrol Hypertens; 2023 May 01; 32(3):263-270. PubMed ID: 36866805
    [Abstract] [Full Text] [Related]

  • 16. Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy.
    Barratt J, Lafayette RA, Rovin BH, Fellström B.
    Expert Rev Clin Immunol; 2023 May 01; 19(7):699-710. PubMed ID: 37103889
    [Abstract] [Full Text] [Related]

  • 17. Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade.
    Chen J, Liu S, Xu H, Wang W, Xie Y, Tang W, Yuan Q, Zheng L, Lin L, Fu S, Shen J.
    Med Sci Monit; 2020 Aug 21; 26():e922839. PubMed ID: 32822333
    [Abstract] [Full Text] [Related]

  • 18. Corticosteroid in IgA nephropathy with moderate proteinuria: A retrospective cohort study.
    Wang Y, Yu J, Jiang Y, Li J, Yimamuyushan A, Xia X, Fan L, Huang F, Chen W, Liu Q.
    Nephrology (Carlton); 2024 May 21; 29(5):268-277. PubMed ID: 38186010
    [Abstract] [Full Text] [Related]

  • 19. Treatment of IgA nephropathy.
    Pozzi C.
    J Nephrol; 2016 Feb 21; 29(1):21-5. PubMed ID: 26577268
    [Abstract] [Full Text] [Related]

  • 20. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
    Liu LJ, Yang YZ, Shi SF, Bao YF, Yang C, Zhu SN, Sui GL, Chen YQ, Lv JC, Zhang H.
    Am J Kidney Dis; 2019 Jul 21; 74(1):15-22. PubMed ID: 30922594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.